UB Paderborn / Katalog / Suche / in CDI

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

Drug discovery today, 2012-09, Vol.17 (17-18), p.988-997

2012

Link zum Volltext

Verfügbarkeit prüfen

FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity

Journal of the American Society of Nephrology, 2018-01, Vol.29 (1), p.118-137

2018

Link zum Volltext

Verfügbarkeit prüfen

Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease

The Journal of biological chemistry, 2013-04, Vol.288 (17), p.11761-11770

2013

Link zum Volltext

Verfügbarkeit prüfen

Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist

Molecular pharmacology, 2010-10, Vol.78 (4), p.617-630

2010

Link zum Volltext

Verfügbarkeit prüfen

The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria

American Journal of Physiology - Renal Physiology, 2009-12, Vol.297 (6), p.F1587-F1596

2009

Link zum Volltext

Verfügbarkeit prüfen

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model

Diabetes (New York, N.Y.), 2010-11, Vol.59 (11), p.2916-2927

2010

Link zum Volltext

Verfügbarkeit prüfen

A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis

The Journal of pharmacology and experimental therapeutics, 2005-08, Vol.314 (2), p.584

2005

Link zum Volltext

Verfügbarkeit prüfen

Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis

The Journal of pharmacology and experimental therapeutics, 2005-05, Vol.313 (2), p.604

2005

Link zum Volltext

Verfügbarkeit prüfen

Targeting bile-acid signalling for metabolic diseases

Nature reviews. Drug discovery, 2008-08, Vol.7 (8), p.678-693

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Gastroenterology (New York, N.Y. 1943), 2013-09, Vol.145 (3), p.574-582.e1

2013

Link zum Volltext

Verfügbarkeit prüfen

Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators

ACS medicinal chemistry letters, 2012-04, Vol.3 (4), p.273-277

2012

Link zum Volltext

Verfügbarkeit prüfen

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

Cell metabolism, 2009-09, Vol.10 (3), p.167-177

2009

Link zum Volltext

Verfügbarkeit prüfen

A dual agonist of farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice

The Journal of biological chemistry, 2017-07, Vol.292 (29), p.12018-12024

2017

Link zum Volltext

Verfügbarkeit prüfen

370-OR: Optimized Weight Loss with Bimagrumab—Reduced Fat Mass with Increased Muscle Mass by Appetite-Independent Mechanisms

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 6α-Ethyl-23(S)-methylcholic Acid (S-EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity

Journal of medicinal chemistry, 2009-12, Vol.52 (24), p.7958-7961

2009

Link zum Volltext

Verfügbarkeit prüfen

Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis

The Journal of pharmacology and experimental therapeutics, 2005-10, Vol.315 (1), p.58

2005

Link zum Volltext

Verfügbarkeit prüfen

Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists

Bioorganic & medicinal chemistry, 2012-06, Vol.20 (11), p.3429-3445

2012

Link zum Volltext

Verfügbarkeit prüfen

Biotech leaders call for free press

Nature biotechnology, 2018-10, Vol.36 (10), p.920-922

2018

Link zum Volltext

Verfügbarkeit prüfen

Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 AgonistS

Molecular pharmacology, 2010-10, Vol.78 (4), p.617-630

2010

Link zum Volltext

Verfügbarkeit prüfen

The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria

American journal of physiology. Renal physiology, 2009, Vol.66 (6)

2009

Link zum Volltext

Verfügbarkeit prüfen

Visit the doctor online

Card technology today, 2002-04, Vol.14 (4), p.7-7

2002

Link zum Volltext

Verfügbarkeit prüfen

The Discovery of Obeticholic Acid (Ocaliva™): First‐in‐Class FXR Agonist

Successful Drug Discovery, 2018, p.197-244

2018

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity

Journal of medicinal chemistry, 2009-12, Vol.52 (24), p.7958-7961

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity

Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease

Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist

The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model

A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis

Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis

Targeting bile-acid signalling for metabolic diseases

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

A dual agonist of farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice

370-OR: Optimized Weight Loss with Bimagrumab—Reduced Fat Mass with Increased Muscle Mass by Appetite-Independent Mechanisms

Discovery of 6α-Ethyl-23(S)-methylcholic Acid (S-EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity

Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis

Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists

Biotech leaders call for free press

Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 AgonistS

The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria

Visit the doctor online

The Discovery of Obeticholic Acid (Ocaliva™): First‐in‐Class FXR Agonist

Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity

Suchergebnisse filtern